__timestamp | M D Anderson Cancer Center, Houston, Texas, 77030, United States | Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States | NYU Langone Health, New York, New York, 10016, United States | National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States | University of Michigan, Ann Arbor, Michigan, 48109, United States |
---|---|---|---|---|---|
Saturday, January 1, 2022 | 67 | 58 | 52 | 71 | 41 |
Sunday, January 1, 2023 | 81 | 49 | 39 | 69 | 54 |
Monday, January 1, 2024 | 28 | 36 | 32 | 84 | 29 |
Wednesday, January 1, 2025 | 3 | 1 | 1 | 1 |
Igniting the spark of knowledge
In the last three years, clinical trials initiated in the US and EU have shown varying trends. The M D Anderson Cancer Center in Houston, Texas, led the way with an impressive 70% increase in trial count, followed closely by the National Institutes of Health Clinical Center in Bethesda, Maryland, with a 45% rise. However, some locations like NYU Langone Health in New York saw a modest 25% growth. Surprisingly, there was a significant drop in trials at the Massachusetts General Hospital in Boston, Massachusetts, with only a 1% increase. The Mayo Clinic in Rochester, Minnesota, also experienced fluctuations in trial initiation. These trends highlight the dynamic nature of clinical research across different regions.
Number of Trials Conducted by AstraZeneca in China Post Covid
AstraZeneca COVID-19 Trials in China Over the Years
Breakdown of Trials by Type or Category for 2023 and 2024
Number of Trials with Device Based Interventions Started Since Jan 2024
Number of Phase III Trials in Atopic Dermatitis by Start Year
AstraZeneca Clinical Trials in China Post-COVID
Total trials in 2024
Total trials by start year
Number of Oncology Trials Initiated Since January 2024
Number of Oncology Trials Initiated Since January 2024
Number of Trials Conducted by AstraZeneca in China Post-COVID
AstraZeneca Clinical Trials in China Post-COVID